Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ondine Biomedical's Total Assets for the quarter that ended in Dec. 2025 was £7.79 Mil.
During the past 12 months, Ondine Biomedical's average Total Assets Growth Rate was 21.80% per year.
During the past 3 years, the average Total Assets Growth Rate was -0.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 5.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 5.30% per year.
During the past 13 years, Ondine Biomedical's highest 3-Year average Total Assets Growth Rate was 668.90%. The lowest was -19.40%. And the median was 6.30%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Ondine Biomedical's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Ondine Biomedical Total Assets Related Terms
Ondine Biomedical Total Assets Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Ondine Biomedical's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ondine Biomedical (LSE:OBI) has a Total Assets of £7.79 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Ondine Biomedical and its competitors.
Is Ondine Biomedical's Total Assets too high?
Ondine Biomedical's current Total Assets is £7.79 Mil. Overall, Ondine Biomedical has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Total Assets compare to VRTX and REGN?
Ondine Biomedical's Total Assets of £7.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current Total Assets is £7.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (LSE:OBI) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.10, compared to a current price of £0.14 — trading 37.5% above its estimated fair value. The current Total Assets is £7.79 Mil. Ondine Biomedical's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Ondine Biomedical (LSE:OBI), the current Total Assets is £7.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (LSE:OBI) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of £0.14 is trading 37.5% above its estimated GF Value™ of £0.10.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for LSE:OBI:
Total Assets: £7.79 Mil
GF Value™: £0.10 vs. price of £0.14 (37.5% above fair value)
No single metric tells the full story. See the LSE:OBI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
26GF Score
Get the complete analysis for LSE:OBI
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OBI has been successfully added to your 
